NASDAQ$VRCA
Verrica Pharmaceuticals Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Verrica reported a net loss for Q3 2020, with increased R&D and G&A expenses, and anticipates resubmitting its NDA for VP-102 in Q1 2021.
Verrica Pharmaceuticals reported a net loss of $10.5 million for the third quarter of 2020. The company is preparing to resubmit its New Drug Application (NDA) for VP-102 in the first quarter of 2021.
- Verrica expects to resubmit its New Drug Application for VP-102 in the first quarter of 2021.
- The positive results from the Company’s two pivotal Phase 3 CAMP studies evaluating the safety and efficacy of VP-102 in children and adults with molluscum were published in the Journal of the American Medical Association (JAMA) Dermatology on September 23, 2020.
- Verrica reported a net loss of $10.5 million for the third quarter of 2020, compared to a $6.1 million net loss for the same period in 2019.
- As of September 30, 2020, Verrica had aggregate cash, cash equivalents, and marketable securities of $71.9 million.
Headline financials
Revenue & EPS history
Verrica · Revenue · Quarterly
$5.02M
Forward guidance
Verrica anticipates resubmitting its NDA for VP-102 in Q1 2021 and believes its cash will support operations through Q4 2021.
Tailwinds
- Expects to resubmit its New Drug Application for VP-102 in the first quarter of 2021
- Believes it has clear alignment on the path forward to resubmit the NDA
- Continued engagement with Torii as they evaluate the option to exclusively license VP-102 in Japan
- Strategically expanded product portfolio into dermatologic cancers
- Cash, cash equivalents, and marketable securities are expected to support operations through the fourth quarter of 2021
Headwinds
- Uncertainties inherent in the drug development process and the regulatory approval process
- Reliance on third parties over which it may not always have full control
- Uncertainties related to the COVID-19 pandemic
- Potential payments by Torii under the Option Agreement should Torii exercise its opinion
- The potential benefits and potential commercialization of VP-102 for the treatment of molluscum, if approved
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-1.1%
Avg return
30 days after
42%
13 / 31 earnings
Positive
+18.6%
Q1 2024
Best reaction
-47.9%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | -15.3% | -19.9% | |
| Q4 2025 | +4.7% | +3.2% | -14.5% | |
| Q3 2025 | +3.2% | +15.8% | +104.7% | |
| Q1 2025 | +2.9% | -0.8% | -3.0% | |
| Q4 2024 | -7.6% | +0.5% | -25.3% | |
| Q3 2024 | -47.9% | -45.8% | -22.2% | |
| Q2 2024 | -44.8% | -43.8% | -62.6% | |
| Q1 2024 | +18.6% | +8.4% | +7.3% | |
| Q4 2023 | -3.0% | -10.1% | +3.5% | |
| Q3 2023 | -13.6% | -17.7% | +7.6% | |
| Q2 2023 | +7.6% | +1.6% | -18.5% | |
| Q1 2023 | -1.4% | -7.1% | -13.9% | |
| Q4 2022 | -6.9% | +1.5% | -21.6% | |
| Q3 2022 | -3.1% | +3.1% | +43.7% | |
| Q2 2022 | +17.1% | +9.6% | +18.8% | |
| Q1 2022 | -1.6% | -7.8% | -63.0% | |
| Q4 2021 | +1.3% | -7.7% | +1.9% | |
| Q3 2021 | -4.2% | -5.9% | -22.2% | |
| Q2 2021 | -1.6% | -0.7% | +12.6% | |
| Q1 2021 | -0.8% | -0.2% | -14.8% | |
| Q4 2020 | -9.6% | -0.2% | +1.3% | |
| Q3 2020 | +13.9% | +13.1% | +32.3% | |
| Q2 2020 | +5.6% | +4.8% | +29.6% | |
| Q1 2020 | +10.5% | +2.8% | +24.0% | |
| Q4 2019 | -12.1% | -7.5% | +31.3% | |
| Q3 2019 | +0.8% | +4.0% | -7.3% | |
| Q2 2019 | +2.6% | -9.3% | -2.3% | |
| Q1 2019 | +1.0% | -3.3% | -23.4% | |
| Q4 2018 | -7.5% | +1.1% | -8.0% | |
| Q3 2018 | -3.8% | +5.6% | -22.7% | |
| Q2 2018 | -0.9% | +2.7% | +13.8% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro